February 27, 2024

Rapid Rise: Codexis (CDXS) Stocks Surge After Key Licensing Deal

Leave a Comment / Mid Day Movers / Fahim Awan

As of the last check this current trading session, Codexis, Inc. (NASDAQ: CDXS) was observed to have surged by 30.47%, reaching $4.18. This upward trend in Codexis stock value is propelled by an announcement of a significant licensing agreement. Codexis (CDXS) has formalized an exclusive, worldwide licensing deal with Roche, pertaining to the Company’s freshly […]

Rapid Rise: Codexis (CDXS) Stocks Surge After Key Licensing Deal Read More »

Viking Therapeutics (VKTX) Shares Rally On Strong Phase 2 Trial Data

Leave a Comment / Mid Day Movers / Fahim Awan

Stock price for Viking Therapeutics, Inc. (NASDAQ: VKTX) jumped 111.23% this current session, reaching $81.28 – a promising sign. Recent favorable clinical outcomes correlate with this increase in VKTX stock price. Viking Therapeutics (VKTX) disclosed encouraging Phase 2 trial findings for VK2735, a medication targeting GLP-1 and GIP receptors, aiming to tackle obesity and metabolic

Viking Therapeutics (VKTX) Shares Rally On Strong Phase 2 Trial Data Read More »

Janux (JANX) Witnesses Dramatic Stock Surge On Promising Clinical Advances

Leave a Comment / Mid Day Movers / Fahim Awan

Janux Therapeutics, Inc. (NASDAQ: JANX) has experienced a notable surge in its stock value, climbing by 193.08% to reach $44.26 on the US charts. This surge is attributed to significant advancements in its clinical development endeavors. The firm is a clinical-stage biopharmaceutical organization that focuses on creating a broad range of cutting-edge immunotherapies. Janux concentrates

Janux (JANX) Witnesses Dramatic Stock Surge On Promising Clinical Advances Read More »

Rapid Rise: Codexis (CDXS) Stocks Surge After Key Licensing Deal

Viking Therapeutics (VKTX) Shares Rally On Strong Phase 2 Trial Data

Janux (JANX) Witnesses Dramatic Stock Surge On Promising Clinical Advances

Stocks
Telegraph

About

Categories

Social Links